Monaco Asset Management SAM Boosts Stake in Nektar Therapeutics (NASDAQ:NKTR)

Monaco Asset Management SAM lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,973,387 shares of the biopharmaceutical company's stock after purchasing an additional 1,163,786 shares during the quarter. Nektar Therapeutics accounts for approximately 1.0% of Monaco Asset Management SAM's investment portfolio, making the stock its 27th largest position. Monaco Asset Management SAM owned 3.13% of Nektar Therapeutics worth $3,375,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of NKTR. RA Capital Management L.P. bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $11,138,000. Acadian Asset Management LLC raised its position in Nektar Therapeutics by 73.5% during the third quarter. Acadian Asset Management LLC now owns 7,626,388 shares of the biopharmaceutical company's stock valued at $4,540,000 after purchasing an additional 3,230,368 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Nektar Therapeutics by 36.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,835,463 shares of the biopharmaceutical company's stock valued at $1,689,000 after purchasing an additional 754,945 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Nektar Therapeutics by 931.5% in the 3rd quarter. GSA Capital Partners LLP now owns 1,841,078 shares of the biopharmaceutical company's stock worth $1,097,000 after purchasing an additional 1,662,589 shares during the period. Finally, Lynx1 Capital Management LP bought a new position in shares of Nektar Therapeutics during the 3rd quarter valued at approximately $1,052,000. Institutional investors own 75.88% of the company's stock.

Wall Street Analyst Weigh In

NKTR has been the topic of a number of analyst reports. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research report on Tuesday, March 5th. Jefferies Financial Group raised their price objective on shares of Nektar Therapeutics from $0.50 to $1.00 and gave the stock a "hold" rating in a research note on Wednesday, March 6th. Finally, StockNews.com assumed coverage on Nektar Therapeutics in a research note on Friday, January 26th. They set a "hold" rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of "Hold" and an average price target of $3.50.

Nektar Therapeutics Stock Up 10.0 %

NKTR traded up $0.16 on Friday, reaching $1.76. 2,360,209 shares of the company traded hands, compared to its average volume of 1,997,249. The company has a market cap of $323.17 million, a P/E ratio of -1.91 and a beta of 0.71. The firm has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $0.78. Nektar Therapeutics has a one year low of $0.41 and a one year high of $1.87.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $21.64 million during the quarter, compared to analyst estimates of $14.91 million. Nektar Therapeutics had a negative return on equity of 101.41% and a negative net margin of 195.02%. During the same quarter in the previous year, the business earned ($0.25) earnings per share. On average, equities analysts forecast that Nektar Therapeutics will post -0.98 earnings per share for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.